Clinical trials: Pre-Dialysis
Hepatitis B
Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™
The current extension study will assess the persistence of anti-HBs antibodies at Months 12, 24 and 36 after primary vaccination with Henogen's HBV vaccine or Fendrix™.
- Trial name
- NCT00445185
- Testing
- Henogen HB vaccine, Fendrix vaccine
- Where
- 23 sites in Belgium, Czechia and 1 more
- Volunteers
- 102 people
- Sponsor
- Henogen
Kidney Failure, Arteriovenous Shunt
Maximizing Native Arteriovenous Fistulae Rates.
The purpose of our study is to compare physical examination alone to color Doppler ultrasonography (CDUS) vascular mapping and physical examination in terms of outcomes of vascular access and long-term patency.
- Conditions
- Kidney Failure, Arteriovenous Shunt, Hemodialysis
- Trial name
- NCT02705417
- Testing
- preoperative color Doppler ultrasonographic vascular mapping, physical examination, medical history
- Volunteers
- 136 people
- Sponsor
- Medifil AE
Chronic Kidney Disease
Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease
The objective of this study is to assess the long-term safety and efficacy of bixalomer under post-marketed setting.
- Trial name
- NCT02805348
- Testing
- Bixalomer
- Where
- 14 sites in Japan
- Volunteers
- 144 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease
Patient INformation About Options for Treatment - PINOT
This prospective observational study is designed to find out what treatment options new patients with chronic kidney disease learn about from their renal unit.
- Trial name
- PINOT (NCT01298115)
- Where
- Australia
- Volunteers
- 721 people
- Sponsor
- University of Sydney
Hepatitis B
A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.
The immune response of uraemic patients to hepatitis B vaccination is impaired compared to healthy subjects. After vaccination, anti-HBs peak antibody concentrations are reduced.
- Trial name
- NCT00291980
- Testing
- HB-AS02V vaccine, HBVAXPRO vaccine
- Where
- 28 sites in Belgium, Czechia and 1 more
- Volunteers
- 185 people
- Sponsor
- Henogen
Chronic Disease, Kidney Diseases
A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients
The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease
- Conditions
- Chronic Disease, Kidney Diseases, Cardiovascular Diseases
- Trial name
- NCT00563355
- Testing
- erythropoietin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Hospital Authority, Hong Kong
Peritoneal Dialysis
Faster Peritoneal Solute Transfer Rate and Survival in a Pre-APD and Icodextrin Peritoneal Dialysis Cohort
A fast peritoneal solute transfer rate (PSTR) has been linked to worse survival especially in continuous ambulatory peritoneal dialysis (PD) cohort.
- Trial name
- NCT05381051
- Volunteers
- 430 people
- Sponsor
- RenJi Hospital
Hepatitis B
Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination
Hepatitis B prevention in non-responders uraemic patients is currently based on both HBsAg surveillance and the isolation from HBsAg carriers. A more immunogenic vaccine would be a benefit for this population.
- Trial name
- NCT00291954
- Testing
- HB-AS02V, HBVAXPRO vaccine
- Where
- 25 sites in Belgium, Czechia and 1 more
- Volunteers
- 257 people
- Sponsor
- Henogen
Pre-dialysis, End Stage Renal Disease
NESP Pediatric Study
Open-label, randomized study of NESP in pediatric subjects 18 years of age or younger. Subjects will receive study drug (NESP or rHuEPO) for 28 weeks after a 2 week screening and baseline period.
- Trial name
- NCT00527137
- Testing
- darbepoetin alfa, rHuEPO
- Volunteers
- 120 people
- Sponsor
- Amgen
Hepatitis B
A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.
The pre-dialysis, peritoneal dialysis and haemodialysis patients would benefit from an improved hepatitis B vaccine, which will elicit stronger and faster cellular and humoral immune responses after the primary vaccination course.
- Trial name
- NCT00291941
- Testing
- Henogen HBV vaccine, FENDRIX
- Where
- 24 sites in Belgium, Czechia and 1 more
- Volunteers
- 300 people
- Sponsor
- Henogen
Chronic Kidney Disease
PINOT Follow-up Study in End-stage Kidney Disease
The primary aims of the Patient INformation about Options for Treatment (PINOT) Follow-up Study are to determine the proportions of patients, identified in the 2009 PINOT cohort that: (i)Made the transition to home dialysis…
- Trial name
- NCT01768624
- Testing
- dialysis, kidney transplant
- Where
- 2 sites in Australia, United Kingdom
- Volunteers
- 721 people
- Sponsor
- University of Sydney